CF-301 Phase III
Clinical Trial Grant
Awarded By
ContraFect Corporation
Start Date
November 15, 2019
End Date
January 31, 2023
Awarded By
ContraFect Corporation
Start Date
November 15, 2019
End Date
January 31, 2023